A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Avacopan in Subjects With Normal Renal Function and Subjects With End-Stage Renal Disease (ESRD) Requiring Hemodialysis
Sponsor: Amgen
A PHASE1 clinical study on End-Stage Renal Disease (ESRD), this trial is completed. The trial is conducted by Amgen and has accumulated 5 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE1
-
Nov 2024 — Oct 2025 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .